Literature DB >> 16244251

Influence of review design on percentages of missed interval breast cancers: retrospective study of interval cancers in a population-based screening program.

Solveig Hofvind1, Per Skaane, Bedrich Vitak, Hege Wang, Steinar Thoresen, Liv Eriksen, Hilde Bjørndal, Audun Braaten, Nils Bjurstam.   

Abstract

PURPOSE: To retrospectively investigate whether different review designs have an influence on the estimate of missed interval cancer in a population-based breast cancer screening program.
MATERIALS AND METHODS: The Norwegian Breast Cancer Screening Program invites women aged 50-69 years to undergo biennial screening mammography. The current study was part of the evaluation and scientific aspects of the screening program and thus was covered by the general ethical approval of the screening program as a part of the Cancer Registry of Norway. All participants signed an informed consent that specified that data related to their screening visit could be used for evaluation and scientific purposes. Six radiologists (9-34 years of experience in mammography) reviewed previously obtained bilateral two-view screening and diagnostic mammograms of 231 interval cancers, 117 screening-detected cancers, and 373 normal cases. Four review designs were used: individual and paired blinded review and individual and consensus informed review. A five-point interpretation scale was used to reclassify the cancers into missed cancers, minimal signs, and true cancers. The number and proportion of subgroups were estimated with 95% confidence intervals.
RESULTS: Of 231 interval cancers, 46 (19.9%) were reclassified as missed cancers with the mixed blinded individual review and 54 (23.4%) were classified as missed cancers with the mixed blinded paired review. Eighty-three cancers (35.9%) were classified as missed cancers with individual informed review, and 78 (33.8%) were classified as missed cancers with consensus informed review. Thirty-nine cancers (16.8%) were reclassified as missed when four or more radiologists assigned a score of 2 or more (probably benign or more suspicious); three cancers (1.3%) were reclassified as missed when a score of 4 or more (probably malignant or more suspicious) was assigned.
CONCLUSION: The percentage of interval cancers classified as missed ranged from 1.3% to 35.9% according to review design. To encourage learning, a review protocol should include both blinded and informed designs.

Entities:  

Mesh:

Year:  2005        PMID: 16244251     DOI: 10.1148/radiol.2372041174

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

1.  Value of audits in breast cancer screening quality assurance programmes.

Authors:  Tanya D Geertse; Roland Holland; Janine M H Timmers; Ellen Paap; Ruud M Pijnappel; Mireille J M Broeders; Gerard J den Heeten
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

2.  Mammography Screening - as of 2013.

Authors:  S Heywang-Koebrunner; K Bock; W Heindel; G Hecht; L Regitz-Jedermann; A Hacker; V Kaeaeb-Sanyal
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-10       Impact factor: 2.915

3.  Mammographic features and histopathological findings of interval breast cancers.

Authors:  S Hofvind; B Geller; P Skaane
Journal:  Acta Radiol       Date:  2008-11       Impact factor: 1.990

4.  Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program.

Authors:  Solveig Hofvind; Berta Geller; Pamela M Vacek; Steinar Thoresen; Per Skaane
Journal:  Eur J Epidemiol       Date:  2007-06-27       Impact factor: 8.082

5.  Unbiased review of digital diagnostic images in practice: informatics prototype and pilot study.

Authors:  Anthony F Fotenos; Nabile M Safdar; Paul G Nagy; Reuben Mezrich; Jonathan S Lewin
Journal:  Acad Radiol       Date:  2012-10-26       Impact factor: 3.173

6.  Can artificial intelligence reduce the interval cancer rate in mammography screening?

Authors:  Kristina Lång; Solveig Hofvind; Alejandro Rodríguez-Ruiz; Ingvar Andersson
Journal:  Eur Radiol       Date:  2021-01-23       Impact factor: 5.315

7.  Prognosis in women with interval breast cancer: population based observational cohort study.

Authors:  Mette Kalager; Rulla M Tamimi; Michael Bretthauer; Hans-Olov Adami
Journal:  BMJ       Date:  2012-11-16

Review 8.  Overdiagnosis and overtreatment of breast cancer: is overdiagnosis an issue for radiologists?

Authors:  Ruth Warren; Asha Eleti
Journal:  Breast Cancer Res       Date:  2006-04-21       Impact factor: 6.466

Review 9.  Benefits and harms of mammography screening.

Authors:  Magnus Løberg; Mette Lise Lousdal; Michael Bretthauer; Mette Kalager
Journal:  Breast Cancer Res       Date:  2015-05-01       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.